Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.84Last Year’s EPS
-0.48Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -10.87%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
Vir Biotechnology reported a transformative year with significant advancements in their pipeline, particularly in the oncology and infectious disease sectors. The financial position is strong with improved cost management leading to a reduced net loss and a solid cash runway. However, the promising clinical results are from heavily pre-treated populations, and there is a reliance on partnerships for the hepatitis B program. Overall, the highlights and strategic advancements outweigh the challenges.Company Guidance
During the call, Vir Biotechnology provided guidance for 2025, highlighting several key metrics and strategic priorities. The company is focused on advancing its ECLIPSE Phase III program for hepatitis delta, which is expected to initiate in the first half of 2025. Vir has secured significant regulatory designations, including FDA breakthrough therapy and Fast Track, as well as EMA PRIME and Orphan Drug status, underscoring the potential impact of its combination therapy. For its oncology portfolio, Vir is progressing with its PRO-XTEN platform, with promising early data in HER2 and PSMA targeted T-cell engagers showing strong clinical activity. The company plans to initiate a Phase I study for its EGFR targeted T-cell engager in the first half of 2025. Financially, Vir reported a strong position with $1.1 billion in cash, cash equivalents, and investments, providing a runway into mid-2027. The company has also achieved significant reductions in R&D and G&A expenses, reflecting a disciplined approach to capital allocation and cost management.Transformative Year for Vir Biotechnology
2024 was described as transformative, with significant strides made in oncology and infectious disease programs, positioning Vir Bio at the forefront of innovative therapies.
ECLIPSE Phase III Program Initiation
Preparations for the ECLIPSE Phase III program in hepatitis delta are underway, with initiation expected in the first half of the year. Regulatory designations received include U.S. FDA breakthrough therapy and Fast Track designation, as well as EMA PRIME designation and Orphan Drug status.
Promising T-cell Engager Results
VIR-5818 and VIR-5500 T-cell engagers showed promising early signs of clinical activity in colorectal and prostate cancer, respectively, with encouraging safety profiles and impressive PSA responses.
Strong Financial Position
The company has a cash runway extending into mid-2027, achieved by significantly reducing operating expenses and cash burn.
Significant Financial Improvements
R&D expenses decreased by approximately 30% year-over-year, and G&A expenses were reduced by 32% year-over-year. Net loss decreased by approximately 32% from the previous year.
---
VIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $9.20 | $8.11 | -11.85% |
| Oct 31, 2024 | $7.49 | $9.26 | +23.63% |
| Aug 01, 2024 | $9.73 | $9.21 | -5.34% |
| May 02, 2024 | $9.18 | $10.39 | +13.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vir Biotechnology (VIR) report earnings?
Vir Biotechnology (VIR) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Vir Biotechnology (VIR) earnings time?
Vir Biotechnology (VIR) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VIR EPS forecast?
VIR EPS forecast for the fiscal quarter 2025 (Q1) is -0.84.
---